Connect with us

Meridia (sibutramine)

Sibutramine (or MERIDIA®) was mainly prescribed to treat obesity.


Class: Anorectic, Serotonin-norepinephrine Reuptake Inhibitor (SNRI),

FDA Approval: 1997

Dosage Forms: 5 mg, 10 mg, 15 mg

Biological Half-life: 1 hour (sibutramine), 14 hours (M1), 16 hours (M2)

Side Effects: Dizziness, blurred vision, dry mouth, nausea, insomnia, constipation, appetite changes, flushing, muscle/joint pain, high blood pressure, tachycardia

Routes of Administration: Oral

Pregnancy Category: C (US)


© 2018 Mental Daily. All Rights Reserved.
Our content is for informational purposes and should not be used as medical or treatment recommendation.